Lonza has announced results for 2019, in which its growth was entirely driven by the Pharma Biotech & Nutrition division on which it will base its future.
CDMO Piramal Pharma Solutions business is to expand its Aurora facility in Aurora, Toronto, by investing C$25 million in a new API wing.
Porton Pharma Solutions, a Chinese custom API services firm, has officially put into use its fermentation pilot laboratory at Chongqing, Sichuan province.
Alcami has agreed to sell its pre-clinical and early stage API facility in Weert, Netherlands, to MercachemSyncom. Terms were not disclosed.
Private equity investor Advent International has acquired Industria Chimica Emiliana (ICE) after 40 years of ownership by the Bortoli family, who developed the first laboratory bile acids.
UK-based biopharmaceuticals producer Mallinckrodt has agreed to sell is CDMO subsidiary BioVectra to HIG Capital, a private equity firm.
Cambrex has signed a definitive agreement to be acquired by an affiliate of private equity firm Permira, which has $48 billion of committed capital in its portfolio, covering healthcare among four other sectors.